Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis

Lisa A Carey; Delphine Loirat; Kevin Punie; Aditya Bardia; Véronique Diéras; Florence Dalenc; Jennifer R Diamond; Christel Fontaine; Grace Wang; Hope S Rugo; Sara A Hurvitz; Kevin Kalinsky; Joyce O'Shaughnessy; Sibylle Loibl; Luca Gianni; Martine Piccart; Yanni Zhu; Rosemary Delaney; See Phan; Javier Cortés

doi:10.1038/s41523-022-00439-5

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis

Lisa A Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Véronique Diéras, Florence Dalenc, Jennifer R Diamond, Christel Fontaine, Grace Wang, Hope S Rugo, Sara A Hurvitz, Kevin Kalinsky, Joyce O'Shaughnessy, Sibylle Loibl, Luca Gianni, Martine Piccart, Yanni Zhu, Rosemary Delaney, See Phan, Javier Cortés

Research output: Contribution to journal › Article › peer-review

43 Citations (Scopus)

19 Downloads (Pure)

Abstract

Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to SN-38 via a hydrolyzable linker, improved outcomes over single-agent chemotherapy of physician's choice (TPC) in metastatic TNBC (mTNBC). Of 468 patients without known baseline brain metastases, 33/235 vs 32/233 patients (both 14%) in the SG vs TPC arms, respectively, received one line of therapy in the metastatic setting and experienced disease recurrence ≤12 months after (neo)adjuvant chemotherapy. SG prolonged progression-free survival (median 5.7 vs 1.5 months [HR, 0.41; 95% CI, 0.22-0.76]) and overall survival (median 10.9 vs 4.9 months [HR, 0.51; 95% CI, 0.28-0.91]) vs TPC, with a manageable safety profile in this subgroup consistent with the overall population. In this second-line setting, as with later-line therapy, SG improved survival over conventional chemotherapy for patients with mTNBC.

Original language	English
Article number	72
Pages (from-to)	1-72
Number of pages	72
Journal	Breast Cancer
Volume	8
Issue number	1
DOIs	https://doi.org/10.1038/s41523-022-00439-5
Publication status	Published - 9 Jun 2022

Bibliographical note

Access to Document

10.1038/s41523-022-00439-5Licence: CC BY

86982970Final published version, 639 KBLicence: CC BY

Cite this

Carey, L. A., Loirat, D., Punie, K., Bardia, A., Diéras, V., Dalenc, F., Diamond, J. R., Fontaine, C., Wang, G., Rugo, H. S., Hurvitz, S. A., Kalinsky, K., O'Shaughnessy, J., Loibl, S., Gianni, L., Piccart, M., Zhu, Y., Delaney, R., Phan, S., & Cortés, J. (2022). Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. Breast Cancer, 8(1), 1-72. [72]. https://doi.org/10.1038/s41523-022-00439-5

Carey, Lisa A ; Loirat, Delphine ; Punie, Kevin ; Bardia, Aditya ; Diéras, Véronique ; Dalenc, Florence ; Diamond, Jennifer R ; Fontaine, Christel ; Wang, Grace ; Rugo, Hope S ; Hurvitz, Sara A ; Kalinsky, Kevin ; O'Shaughnessy, Joyce ; Loibl, Sibylle ; Gianni, Luca ; Piccart, Martine ; Zhu, Yanni ; Delaney, Rosemary ; Phan, See ; Cortés, Javier. / Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. In: Breast Cancer. 2022 ; Vol. 8, No. 1. pp. 1-72.

@article{3a137b3d726044caa2a99fde6f81fcd2,

title = "Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis",

abstract = "Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to SN-38 via a hydrolyzable linker, improved outcomes over single-agent chemotherapy of physician's choice (TPC) in metastatic TNBC (mTNBC). Of 468 patients without known baseline brain metastases, 33/235 vs 32/233 patients (both 14%) in the SG vs TPC arms, respectively, received one line of therapy in the metastatic setting and experienced disease recurrence ≤12 months after (neo)adjuvant chemotherapy. SG prolonged progression-free survival (median 5.7 vs 1.5 months [HR, 0.41; 95% CI, 0.22-0.76]) and overall survival (median 10.9 vs 4.9 months [HR, 0.51; 95% CI, 0.28-0.91]) vs TPC, with a manageable safety profile in this subgroup consistent with the overall population. In this second-line setting, as with later-line therapy, SG improved survival over conventional chemotherapy for patients with mTNBC.",

author = "Carey, {Lisa A} and Delphine Loirat and Kevin Punie and Aditya Bardia and V{\'e}ronique Di{\'e}ras and Florence Dalenc and Diamond, {Jennifer R} and Christel Fontaine and Grace Wang and Rugo, {Hope S} and Hurvitz, {Sara A} and Kevin Kalinsky and Joyce O'Shaughnessy and Sibylle Loibl and Luca Gianni and Martine Piccart and Yanni Zhu and Rosemary Delaney and See Phan and Javier Cort{\'e}s",

note = "{\textcopyright} 2022. The Author(s).",

year = "2022",

month = jun,

day = "9",

doi = "10.1038/s41523-022-00439-5",

language = "English",

volume = "8",

pages = "1--72",

journal = "Breast Cancer",

issn = "1340-6868",

publisher = "Springer Japan",

number = "1",

}

Carey, LA, Loirat, D, Punie, K, Bardia, A, Diéras, V, Dalenc, F, Diamond, JR, Fontaine, C, Wang, G, Rugo, HS, Hurvitz, SA, Kalinsky, K, O'Shaughnessy, J, Loibl, S, Gianni, L, Piccart, M, Zhu, Y, Delaney, R, Phan, S & Cortés, J 2022, 'Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis', Breast Cancer, vol. 8, no. 1, 72, pp. 1-72. https://doi.org/10.1038/s41523-022-00439-5

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis. / Carey, Lisa A; Loirat, Delphine; Punie, Kevin; Bardia, Aditya; Diéras, Véronique; Dalenc, Florence; Diamond, Jennifer R; Fontaine, Christel; Wang, Grace; Rugo, Hope S; Hurvitz, Sara A; Kalinsky, Kevin; O'Shaughnessy, Joyce; Loibl, Sibylle; Gianni, Luca; Piccart, Martine; Zhu, Yanni; Delaney, Rosemary; Phan, See; Cortés, Javier.

In: Breast Cancer, Vol. 8, No. 1, 72, 09.06.2022, p. 1-72.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis

AU - Carey, Lisa A

AU - Loirat, Delphine

AU - Punie, Kevin

AU - Bardia, Aditya

AU - Diéras, Véronique

AU - Dalenc, Florence

AU - Diamond, Jennifer R

AU - Fontaine, Christel

AU - Wang, Grace

AU - Rugo, Hope S

AU - Hurvitz, Sara A

AU - Kalinsky, Kevin

AU - O'Shaughnessy, Joyce

AU - Loibl, Sibylle

AU - Gianni, Luca

AU - Piccart, Martine

AU - Zhu, Yanni

AU - Delaney, Rosemary

AU - Phan, See

AU - Cortés, Javier

PY - 2022/6/9

Y1 - 2022/6/9

N2 - Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to SN-38 via a hydrolyzable linker, improved outcomes over single-agent chemotherapy of physician's choice (TPC) in metastatic TNBC (mTNBC). Of 468 patients without known baseline brain metastases, 33/235 vs 32/233 patients (both 14%) in the SG vs TPC arms, respectively, received one line of therapy in the metastatic setting and experienced disease recurrence ≤12 months after (neo)adjuvant chemotherapy. SG prolonged progression-free survival (median 5.7 vs 1.5 months [HR, 0.41; 95% CI, 0.22-0.76]) and overall survival (median 10.9 vs 4.9 months [HR, 0.51; 95% CI, 0.28-0.91]) vs TPC, with a manageable safety profile in this subgroup consistent with the overall population. In this second-line setting, as with later-line therapy, SG improved survival over conventional chemotherapy for patients with mTNBC.

AB - Patients with triple-negative breast cancer (TNBC) who relapse early after (neo)adjuvant chemotherapy have more aggressive disease. In the ASCENT trial, sacituzumab govitecan (SG), an antibody-drug conjugate composed of an anti-Trop-2 antibody coupled to SN-38 via a hydrolyzable linker, improved outcomes over single-agent chemotherapy of physician's choice (TPC) in metastatic TNBC (mTNBC). Of 468 patients without known baseline brain metastases, 33/235 vs 32/233 patients (both 14%) in the SG vs TPC arms, respectively, received one line of therapy in the metastatic setting and experienced disease recurrence ≤12 months after (neo)adjuvant chemotherapy. SG prolonged progression-free survival (median 5.7 vs 1.5 months [HR, 0.41; 95% CI, 0.22-0.76]) and overall survival (median 10.9 vs 4.9 months [HR, 0.51; 95% CI, 0.28-0.91]) vs TPC, with a manageable safety profile in this subgroup consistent with the overall population. In this second-line setting, as with later-line therapy, SG improved survival over conventional chemotherapy for patients with mTNBC.

UR - http://www.scopus.com/inward/record.url?scp=85131747486&partnerID=8YFLogxK

U2 - 10.1038/s41523-022-00439-5

DO - 10.1038/s41523-022-00439-5

M3 - Article

C2 - 35680967

VL - 8

SP - 1

EP - 72

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 1

M1 - 72

ER -

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this